These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 28400475)

  • 1. An
    Silva A; Silva MC; Sudalagunta P; Distler A; Jacobson T; Collins A; Nguyen T; Song J; Chen DT; Chen L; Cubitt C; Baz R; Perez L; Rebatchouk D; Dalton W; Greene J; Gatenby R; Gillies R; Sontag E; Meads MB; Shain KH
    Cancer Res; 2017 Jun; 77(12):3336-3351. PubMed ID: 28400475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pharmacodynamic model of clinical synergy in multiple myeloma.
    Sudalagunta P; Silva MC; Canevarolo RR; Alugubelli RR; DeAvila G; Tungesvik A; Perez L; Gatenby R; Gillies R; Baz R; Meads MB; Shain KH; Silva AS
    EBioMedicine; 2020 Apr; 54():102716. PubMed ID: 32268267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP).
    Rashid MBMA; Toh TB; Hooi L; Silva A; Zhang Y; Tan PF; Teh AL; Karnani N; Jha S; Ho CM; Chng WJ; Ho D; Chow EK
    Sci Transl Med; 2018 Aug; 10(453):. PubMed ID: 30089632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study.
    Richardson PG; Bringhen S; Voorhees P; Plesner T; Mellqvist UH; Reeves B; Paba-Prada C; Zubair H; Byrne C; Chauhan D; Anderson K; Nordström E; Harmenberg J; Palumbo A; Sonneveld P
    Lancet Haematol; 2020 May; 7(5):e395-e407. PubMed ID: 32213344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial.
    Yee AJ; Bensinger WI; Supko JG; Voorhees PM; Berdeja JG; Richardson PG; Libby EN; Wallace EE; Birrer NE; Burke JN; Tamang DL; Yang M; Jones SS; Wheeler CA; Markelewicz RJ; Raje NS
    Lancet Oncol; 2016 Nov; 17(11):1569-1578. PubMed ID: 27646843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors.
    Turner JG; Dawson JL; Grant S; Shain KH; Dalton WS; Dai Y; Meads M; Baz R; Kauffman M; Shacham S; Sullivan DM
    J Hematol Oncol; 2016 Aug; 9(1):73. PubMed ID: 27557643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simplified response monitoring criteria for multiple myeloma in patients undergoing therapy with novel agents using computed tomography.
    Schabel C; Horger M; Kum S; Weisel K; Fritz J; Ioanoviciu SD; Bier G
    Eur J Radiol; 2016 Dec; 85(12):2195-2199. PubMed ID: 27842666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot study of 3D tissue-engineered bone marrow culture as a tool to predict patient response to therapy in multiple myeloma.
    Alhallak K; Jeske A; de la Puente P; Sun J; Fiala M; Azab F; Muz B; Sahin I; Vij R; DiPersio JF; Azab AK
    Sci Rep; 2021 Sep; 11(1):19343. PubMed ID: 34588522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma.
    Vogl DT; Raje N; Jagannath S; Richardson P; Hari P; Orlowski R; Supko JG; Tamang D; Yang M; Jones SS; Wheeler C; Markelewicz RJ; Lonial S
    Clin Cancer Res; 2017 Jul; 23(13):3307-3315. PubMed ID: 28053023
    [No Abstract]   [Full Text] [Related]  

  • 10. Venetoclax for the treatment of multiple myeloma.
    Vaxman I; Sidiqi MH; Gertz M
    Expert Rev Hematol; 2018 Dec; 11(12):915-920. PubMed ID: 30428277
    [No Abstract]   [Full Text] [Related]  

  • 11. Sorafenib has potent antitumor activity against multiple myeloma in vitro, ex vivo, and in vivo in the 5T33MM mouse model.
    Kharaziha P; De Raeve H; Fristedt C; Li Q; Gruber A; Johnsson P; Kokaraki G; Panzar M; Laane E; Osterborg A; Zhivotovsky B; Jernberg-Wiklund H; Grandér D; Celsing F; Björkholm M; Vanderkerken K; Panaretakis T
    Cancer Res; 2012 Oct; 72(20):5348-62. PubMed ID: 22952216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A preclinical assay for chemosensitivity in multiple myeloma.
    Khin ZP; Ribeiro ML; Jacobson T; Hazlehurst L; Perez L; Baz R; Shain K; Silva AS
    Cancer Res; 2014 Jan; 74(1):56-67. PubMed ID: 24310398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Bcl-2 for the treatment of multiple myeloma.
    Touzeau C; Maciag P; Amiot M; Moreau P
    Leukemia; 2018 Sep; 32(9):1899-1907. PubMed ID: 30076373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib and its role in the management of patients with multiple myeloma.
    Orlowski RZ
    Expert Rev Anticancer Ther; 2004 Apr; 4(2):171-9. PubMed ID: 15056047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determining therapeutic susceptibility in multiple myeloma by single-cell mass accumulation.
    Cetin AE; Stevens MM; Calistri NL; Fulciniti M; Olcum S; Kimmerling RJ; Munshi NC; Manalis SR
    Nat Commun; 2017 Nov; 8(1):1613. PubMed ID: 29151572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma.
    Podar K; Pecherstorfer M
    Expert Opin Pharmacother; 2017 Aug; 18(11):1061-1079. PubMed ID: 28604120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.
    Punnoose EA; Leverson JD; Peale F; Boghaert ER; Belmont LD; Tan N; Young A; Mitten M; Ingalla E; Darbonne WC; Oleksijew A; Tapang P; Yue P; Oeh J; Lee L; Maiga S; Fairbrother WJ; Amiot M; Souers AJ; Sampath D
    Mol Cancer Ther; 2016 May; 15(5):1132-44. PubMed ID: 26939706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New aspects in the clinical course determination and therapy in multiple myeloma].
    Ludwig H; Pietschmann H
    Acta Med Austriaca; 1979; 6(5):255-60. PubMed ID: 555224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells.
    Silva A; Jacobson T; Meads M; Distler A; Shain K
    J Vis Exp; 2015 Jul; (101):e53070. PubMed ID: 26274375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting the impact of combined therapies on myeloma cell growth using a hybrid multi-scale agent-based model.
    Ji Z; Su J; Wu D; Peng H; Zhao W; Nlong Zhao B; Zhou X
    Oncotarget; 2017 Jan; 8(5):7647-7665. PubMed ID: 28032590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.